| Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study DR Gandara, J von Pawel, J Mazieres, R Sullivan, Å Helland, JY Han, ... Journal of Thoracic Oncology 13 (12), 1906-1918, 2018 | 105 | 2018 |
| Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial ES Kim, V Velcheti, T Mekhail, C Yun, SM Shagan, S Hu, YK Chae, ... Nature medicine 28 (5), 939-945, 2022 | 95 | 2022 |
| Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in … M Socinski, V Velcheti, T Mekhail, YK Chae, TA Leal, JE Dowell, ML Tsai, ... Annals of Oncology 30, v919-v920, 2019 | 66 | 2019 |
| Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in … ES Kim, V Velcheti, T Mekhail, TA Leal, JE Dowell, ML Tsai, CSR Dakhil, ... Annals of Oncology 29, viii744, 2018 | 64 | 2018 |
| Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma K Raghav, S Liu, MJ Overman, AF Willett, M Knafl, SC Fu, A Malpica, ... Cancer discovery 11 (11), 2738-2747, 2021 | 52 | 2021 |
| Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC … V Velcheti, ES Kim, T Mekhail, C Dakhil, PJ Stella, X Shen, S Hu, SM Paul, ... Journal of Clinical Oncology 36 (15_suppl), 12001-12001, 2018 | 42 | 2018 |
| A phase II trial of atezolizumab and bevacizumab in patients with advanced, progressive neuroendocrine tumors (NETs). DM Halperin, S Liu, A Dasari, DR Fogelman, P Bhosale, A Mahvash, ... Journal of Clinical Oncology 38 (4_suppl), 619-619, 2020 | 36 | 2020 |
| Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. DR Gandara, J Von Pawel, RN Sullivan, A Helland, JY Han, S Ponce Aix, ... Journal of Clinical Oncology 35 (15_suppl), 9001-9001, 2017 | 32 | 2017 |
| Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: a nonrandomized clinical trial DM Halperin, S Liu, A Dasari, D Fogelman, P Bhosale, A Mahvash, ... JAMA oncology 8 (6), 904-909, 2022 | 22 | 2022 |
| Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor … TSK Mok, S Gadgeel, ES Kim, V Velcheti, S Hu, T Riehl, E Schleifman, ... Annals of Oncology 28, v494-v495, 2017 | 21 | 2017 |
| Impact of immune checkpoint inhibitors on COVID-19 severity in patients with cancer R Tan, C Yun, A Seetasith, D Sheinson, R Walls, I Ngwa, JC Reddy, ... The Oncologist 27 (3), 236-243, 2022 | 15 | 2022 |
| Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly … SPS Weathers, C Kamiya-Matsuoka, RA Harrison, DD Liu, S Dervin, ... Journal of Clinical Oncology 38 (15_suppl), 2511-2511, 2020 | 15 | 2020 |
| Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a phase II … MA Socinski, SM Paul, C Yun, S Hu, V Shen, V Velcheti, TS Mok, ... Cancer Research 79 (13_Supplement), CT194-CT194, 2019 | 8 | 2019 |
| Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide … SPS Weathers, H Zhu, M Knafl, A Damania, C Kamiya-Matsuoka, ... Journal of Clinical Oncology 40 (16_suppl), 2006-2006, 2022 | 5 | 2022 |
| A phase II trial of atezolizumab and bevacizumab in patients with relapsed/refractory and unresectable malignant peritoneal mesothelioma. KPS Raghav, MJ Overman, S Liu, A Willett, RE Royal, A Malpica, C Scally, ... Journal of Clinical Oncology 38 (15_suppl), 9013-9013, 2020 | 5 | 2020 |
| Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study F De Marinis, F Barlesi, A Rittmeyer, J von Pawel, JY Han, M Kozloff, ... Annals of Oncology 28, v467, 2017 | 5 | 2017 |
| Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC). R Ferrarotto, J Mata, F Mott, P Bhosale, ML Rubin, M Altan, S Dervin, ... Journal of Clinical Oncology 37 (15_suppl), e21006-e21006, 2019 | 4 | 2019 |
| PS01. 54: evaluation of novel blood-based biomarkers with atezolizumab monotherapy in 1L advanced or metastatic NSCLC (B-F1RST): topic: medical oncology MA Socinski, J Schiller, S Dakhil, S Kazmi, J Leach, S Hu, SM Paul, ... Journal of Thoracic Oncology 11 (11), S303-S304, 2016 | 4 | 2016 |
| Ctim-04. Biomarker immune correlates in newly diagnosed glioblastoma (Gbm) treated with atezolizumab in combination with temozolomide (Tmz) and radiation SP Weathers, M Knafl, E Parra, S Hernandez, L Solis, BS Espiridion, ... Neuro-Oncology 23 (Supplement_6), vi49-vi49, 2021 | 1 | 2021 |
| Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study LG de Sousa, S Liu, P Bhosale, M Altan, W Darbonne, K Schulze, ... Oral oncology 151, 106747, 2024 | | 2024 |
